19d
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial ( NCT04534205 ) for ...
Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...
A Delaware federal judge on Monday rejected requests from Pfizer (PFE), BioNTech (BNTX), and Moderna (MRNA) to dismiss lawsuits filed against them by Bayer's (BAYZF)(BAYRY) Monsanto unit regarding the ...
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...
LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...
BioNTech (BNTX) ADRs lost ~5% in the premarket on Thursday after Bloomberg News reported that Pfizer (PFE) is planning to sell its remaining stake in its partner, which helped the U.S. pharma giant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results